Cargando…
Pharmacokinetics of a Long-Acting Nanoformulated Dolutegravir Prodrug in Rhesus Macaques
A nanoformulated myristoylated dolutegravir prodrug (NMDTG) was prepared using good laboratory practice protocols. Intramuscular injection of NMDTG (118 ± 8 mg/ml, 25.5 mg of DTG equivalents/kg of body weight) to three rhesus macaques led to plasma DTG levels of 86 ± 12 and 28 ± 1 ng/ml on days 35 a...
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Society for Microbiology
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5740312/ https://www.ncbi.nlm.nih.gov/pubmed/29061742 http://dx.doi.org/10.1128/AAC.01316-17 |
| _version_ | 1783288015521579008 |
|---|---|
| author | McMillan, JoEllyn Szlachetka, Adam Slack, Lara Sillman, Brady Lamberty, Benjamin Morsey, Brenda Callen, Shannon Gautam, Nagsen Alnouti, Yazen Edagwa, Benson Gendelman, Howard E. Fox, Howard S. |
| author_facet | McMillan, JoEllyn Szlachetka, Adam Slack, Lara Sillman, Brady Lamberty, Benjamin Morsey, Brenda Callen, Shannon Gautam, Nagsen Alnouti, Yazen Edagwa, Benson Gendelman, Howard E. Fox, Howard S. |
| author_sort | McMillan, JoEllyn |
| collection | PubMed |
| description | A nanoformulated myristoylated dolutegravir prodrug (NMDTG) was prepared using good laboratory practice protocols. Intramuscular injection of NMDTG (118 ± 8 mg/ml, 25.5 mg of DTG equivalents/kg of body weight) to three rhesus macaques led to plasma DTG levels of 86 ± 12 and 28 ± 1 ng/ml on days 35 and 91, respectively. The NMDTG platform showed no significant adverse events. Further modification may further extend the drug's apparent half-life for human use. |
| format | Online Article Text |
| id | pubmed-5740312 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2017 |
| publisher | American Society for Microbiology |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-57403122017-12-26 Pharmacokinetics of a Long-Acting Nanoformulated Dolutegravir Prodrug in Rhesus Macaques McMillan, JoEllyn Szlachetka, Adam Slack, Lara Sillman, Brady Lamberty, Benjamin Morsey, Brenda Callen, Shannon Gautam, Nagsen Alnouti, Yazen Edagwa, Benson Gendelman, Howard E. Fox, Howard S. Antimicrob Agents Chemother Antiviral Agents A nanoformulated myristoylated dolutegravir prodrug (NMDTG) was prepared using good laboratory practice protocols. Intramuscular injection of NMDTG (118 ± 8 mg/ml, 25.5 mg of DTG equivalents/kg of body weight) to three rhesus macaques led to plasma DTG levels of 86 ± 12 and 28 ± 1 ng/ml on days 35 and 91, respectively. The NMDTG platform showed no significant adverse events. Further modification may further extend the drug's apparent half-life for human use. American Society for Microbiology 2017-12-21 /pmc/articles/PMC5740312/ /pubmed/29061742 http://dx.doi.org/10.1128/AAC.01316-17 Text en Copyright © 2017 McMillan et al. https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Antiviral Agents McMillan, JoEllyn Szlachetka, Adam Slack, Lara Sillman, Brady Lamberty, Benjamin Morsey, Brenda Callen, Shannon Gautam, Nagsen Alnouti, Yazen Edagwa, Benson Gendelman, Howard E. Fox, Howard S. Pharmacokinetics of a Long-Acting Nanoformulated Dolutegravir Prodrug in Rhesus Macaques |
| title | Pharmacokinetics of a Long-Acting Nanoformulated Dolutegravir Prodrug in Rhesus Macaques |
| title_full | Pharmacokinetics of a Long-Acting Nanoformulated Dolutegravir Prodrug in Rhesus Macaques |
| title_fullStr | Pharmacokinetics of a Long-Acting Nanoformulated Dolutegravir Prodrug in Rhesus Macaques |
| title_full_unstemmed | Pharmacokinetics of a Long-Acting Nanoformulated Dolutegravir Prodrug in Rhesus Macaques |
| title_short | Pharmacokinetics of a Long-Acting Nanoformulated Dolutegravir Prodrug in Rhesus Macaques |
| title_sort | pharmacokinetics of a long-acting nanoformulated dolutegravir prodrug in rhesus macaques |
| topic | Antiviral Agents |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5740312/ https://www.ncbi.nlm.nih.gov/pubmed/29061742 http://dx.doi.org/10.1128/AAC.01316-17 |
| work_keys_str_mv | AT mcmillanjoellyn pharmacokineticsofalongactingnanoformulateddolutegravirprodruginrhesusmacaques AT szlachetkaadam pharmacokineticsofalongactingnanoformulateddolutegravirprodruginrhesusmacaques AT slacklara pharmacokineticsofalongactingnanoformulateddolutegravirprodruginrhesusmacaques AT sillmanbrady pharmacokineticsofalongactingnanoformulateddolutegravirprodruginrhesusmacaques AT lambertybenjamin pharmacokineticsofalongactingnanoformulateddolutegravirprodruginrhesusmacaques AT morseybrenda pharmacokineticsofalongactingnanoformulateddolutegravirprodruginrhesusmacaques AT callenshannon pharmacokineticsofalongactingnanoformulateddolutegravirprodruginrhesusmacaques AT gautamnagsen pharmacokineticsofalongactingnanoformulateddolutegravirprodruginrhesusmacaques AT alnoutiyazen pharmacokineticsofalongactingnanoformulateddolutegravirprodruginrhesusmacaques AT edagwabenson pharmacokineticsofalongactingnanoformulateddolutegravirprodruginrhesusmacaques AT gendelmanhowarde pharmacokineticsofalongactingnanoformulateddolutegravirprodruginrhesusmacaques AT foxhowards pharmacokineticsofalongactingnanoformulateddolutegravirprodruginrhesusmacaques |